Format

Send to

Choose Destination
BMC Cancer. 2014 Jul 21;14:525. doi: 10.1186/1471-2407-14-525.

Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.

Author information

1
PET Center, Kofu Neurosurgical Hospital, Sakaori 1-16-18, Kofu City, Yamanashi Prefecture, Japan. pecampecam@yahoo.co.jp.

Abstract

BACKGROUND:

In this retrospective study, the authors evaluated the prognostic value of whole-body total lesion glycolysis (WTLG) on FDG/PET images in metastatic breast cancer (MBC) patients.

METHODS:

We retrospectively evaluated 54 MBC patients who were diagnosed as having one or more metastatic lesions between June 2005 and March 2013. Twenty-four patients were diagnosed at the initial presentation (group A) and 30 patients were diagnosed for the first time at some point after a surgery (group B). Patients were excluded if they had received chemotherapy within 30 days before PET/CT. SUVmax and total TLG were calculated for all lesions in each patient and the highest SUVmax and the whole-body TLG (WTLG) values were used as independent variables for the analyses. Mean ages and the proportions of histopathological subtypes were compared between two groups using Mann-Whitney U test and Fisher's exact test, respectively. The prognostic significance of PET parameters was assessed using Cox proportional hazards regression analysis.

RESULTS:

For groups A and B, the median follow-up period was 26 months (range, 3-58 months) and 40.5 months (range, 3-69 months), and the median age was 61 years (range, 42-81 years) and 59 years (range, 24-74 years), respectively. There were no significant differences between two groups in age (p = 0.294) or histopathological subtype (p = 0.384). In the univariate analyses, WTLG was found to be significantly associated with overall survival (OS) for patients of group A (p = 0.012). In the multivariate analysis, WTLG was also significantly associated with OS (p = 0.015). Only hormonal receptor level was a significant indicator of longer OS in patients with recurrent MBC (group B).

CONCLUSIONS:

This study demonstrated that WTLG on PET/CT is an independent prognostic factor for survival in breast cancer patients with metastases at the initial presentation.

PMID:
25048880
PMCID:
PMC4223546
DOI:
10.1186/1471-2407-14-525
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center